leadf
logo-loader
viewDestiny Pharma PLC

Destiny Pharma mark 'exciting time, completing studies and delivering data'

Destiny Pharma PLC's (LON:DEST) Neil Clarke talks to Proactive London's Katie Pilbeam about the XF-73 Phase 2b clinical trial which is now fully recruited. 

The plan is to finalise the phase 2 data in the first quarter then move on to phase 3, with discussions already taking place as to how this is going to work, in regards to the amount of patients that will be taking part. 

Destiny is focused on medicines that can prevent life-threatening infections after operations in hospitals. XF-73 is designed to prevent post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

Quick facts: Destiny Pharma PLC

Price: 125 GBX

AIM:DEST
Market: AIM
Market Cap: £74.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma presents at the Proactive One2One live investment forum

  Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its...

5 days ago

2 min read